
  
    
      
        
        On_IN May_NNP 15_CD ,_, 2005_CD ,_, the_DT Public_NNP Library_NNP of_IN Science_NNP and_CC the_DT Government_NNP Accountability_NNP
        Project_NNP ,_, a_DT public_JJ interest_NN legal_JJ group_NN that_WDT advises_VBZ and_CC supports_VBZ whistleblowers_NNS
        (_( www_NN ._. whistleblower_NN ._. org_NN )_) ,_, co-sponsored_JJ a_DT private_JJ meeting_NN near_IN the_DT Capitol_NNP Building_NNP in_IN
        Washington_NNP ,_, D_NNP ._. C_NNP ._. In_IN the_DT room_NN were_VBD four_CD of_IN the_DT most_RBS high_JJ profile_NN medical_JJ whistleblowers_NNS of_IN
        recent_JJ times_NNS ._. All_DT four_CD have_VBP gone_VBN public_NN with_IN information_NN about_IN practices_NNS in_IN medicine_NN and_CC
        medical_JJ research_NN that_IN they_PRP believe_VBP are_VBP risking_VBG the_DT public_NN 's_POS health_NN or_CC safety_NN [_NN 1_CD –_NN 5_CD ]_NN ._. One_CD of_IN
        them_PRP was_VBD David_NNP Graham_NNP ,_, Associate_NNP Director_NNP in_IN the_DT United_NNP States_NNPS Food_NNP and_CC Drug_NNP
        Administration_NNP 's_POS (_( FDA_NNP 's_POS )_) Office_NNP of_IN Drug_NNP Safety_NNP ,_, whose_WP$ research_NN on_IN rofecoxib_NN (_( Vioxx_NNP )_) pointed_VBD
        to_TO the_DT serious_JJ cardiovascular_JJ risks_NNS of_IN the_DT drug_NN [_NN 1_CD ]_NN ._. Graham_NNP was_VBD speaking_VBG in_IN his_PRP$ own_JJ
        capacity_NN and_CC was_VBD not_RB representing_VBG the_DT FDA_NNP ._. An_DT anonymous_JJ fifth_JJ whistleblower—a_NN research_NN
        scientist_NN at_IN a_DT major_JJ drug_NN company—participated_JJ by_IN phone_NN ._.
        The_DT whistleblowers_NNS took_VBD turns_VBZ to_TO share_VB their_PRP$ stories_NNS ,_, including_VBG their_PRP$ accounts_NNS of_IN
        retaliations_NNS they_PRP said_VBD they_PRP had_VBD faced_VBN from_IN their_PRP$ employers_NNS on_IN raising_VBG their_PRP$ concerns_NNS ,_, which_WDT
        led_VBD to_TO lawsuits_NNS by_IN at_IN least_JJS two_CD of_IN the_DT whistleblowers_NNS [_NN 2_CD ,_, 3_CD ]_NN ._. The_DT picture_NN that_WDT emerged_VBD from_IN
        these_DT accounts—a_NN picture_NN of_IN American_JJ medicine_NN 's_POS inappropriate_JJ ties_NNS with_IN the_DT pharmaceutical_JJ
        industry—was_NNS deeply_RB troubling_JJ ._.
        As_IN the_DT investigative_JJ medical_JJ journalist_NN Jeanne_NNP Lenzer_NNP reports_NNS in_IN her_PRP$ Essay_NNP for_IN 
        PLoS_NNP Medicine_NNP [_NN 6_CD ]_NN ,_, the_DT whistleblowers_NNS spoke_VBD of_IN public_JJ regulatory_JJ agencies_NNS
        that_WDT are_VBP putting_VBG the_DT interests_NNS of_IN drug_NN companies_NNS ahead_RB of_IN the_DT safety_NN of_IN patients_NNS ,_, and_CC of_IN
        pharmaceutical_JJ companies_NNS that_WDT allow_VBP their_PRP$ marketing_NN departments_NNS to_TO knowingly_RB downplay_NN
        serious_JJ side_NN effects_NNS when_WRB promoting_VBG their_PRP$ drugs_NNS ._. And_CC they_PRP spoke_VBD of_IN the_DT woefully_RB inadequate_JJ
        protection_NN offered_VBN to_TO those_DT in_IN the_DT medical_JJ community_NN who_WP feel_VBP morally_RB compelled_VBN to_TO blow_VB the_DT
        whistle_VBP ._.
        It_PRP was_VBD Lenzer_NNP who_WP conceived_VBD the_DT idea_NN for_IN the_DT meeting_NN ._. She_PRP believed_VBD that_IN important_JJ
        lessons_NNS would_MD emerge_VB from_IN having_VBG these_DT medical_JJ whistleblowers_NNS ,_, who_WP come_VBP from_IN very_RB different_JJ
        professional_JJ backgrounds_NNS ,_, together_RB in_IN one_CD room_NN to_TO share_VB their_PRP$ experiences_NNS ._. It_PRP took_VBD her_PRP$ many_JJ
        months_NNS of_IN planning_NN ._. In_IN particular_JJ ,_, she_PRP needed_VBD to_TO gain_VB the_DT trust_NN of_IN the_DT industry_NN research_NN
        scientist_NN ,_, so_IN that_IN the_DT scientist_NN could_MD feel_VB sure_JJ that_DT anonymity_NN would_MD be_VB preserved_VBN ._. But_CC all_DT
        of_IN her_PRP$ planning_NN nearly_RB came_VBD to_TO nothing_NN ._. At_IN the_DT last_JJ moment_NN the_DT original_JJ journal_NN sponsor_NN
        pulled_VBD out_IN on_IN the_DT advice_NN of_IN its_PRP$ lawyers_NNS ._.
        
          
            
              The_DT picture_NN that_WDT emerged_VBD from_IN these_DT accounts_NNS was_VBD deeply_RB troubling_JJ ._.
            
          
        
        Lenzer_NNP 's_POS phone_NN call_NN to_TO PLoS_NNP ,_, enquiring_VBG whether_IN we_PRP might_MD step_VB in_IN ,_, came_VBD just_RB ten_CD days_NNS
        before_IN the_DT event_NN was_VBD due_JJ to_TO happen_VB ._. We_PRP took_VBD our_PRP$ own_JJ legal_JJ advice_NN and_CC then_RB agreed_VBD to_TO sponsor_VB
        the_DT roundtable_JJ ._. PLoS_NNP was_VBD eager_JJ to_TO support_VB this_DT event_NN ,_, and_CC willing_JJ to_TO accept_VB any_DT small_JJ legal_JJ
        risks_NNS ,_, because_IN we_PRP believe_VBP that_IN the_DT issues_NNS raised_VBD will_MD be_VB of_IN huge_JJ interest_NN to_TO the_DT medical_JJ
        community_NN ,_, to_TO the_DT press_NN ,_, to_TO patients_NNS ,_, and_CC to_TO the_DT broader_JJR public_JJ ._. Further_RB ,_, the_DT event_NN fits_VBZ
        well_RB with_IN our_PRP$ own_JJ public_JJ service_NN mission_NN of_IN making_VBG all_DT scientific_JJ and_CC medical_JJ research_NN
        results_NNS freely_RB and_CC publicly_RB available_JJ ,_, and_CC with_IN our_PRP$ belief_NN that_DT transparency_NN in_IN the_DT conduct_NN
        and_CC publication_NN of_IN research_NN is_VBZ important_JJ for_IN public_JJ trust_NN ._. And_CC the_DT topic_NN of_IN the_DT roundtable_JJ
        was_VBD in_IN line_NN with_IN other_JJ articles_NNS we_PRP have_VBP published_VBN highlighting_VBG the_DT many_JJ ways_NNS in_IN which_WDT
        medicine_NN has_VBZ become_VBN tightly_RB entangled_VBN with_IN industry_NN ,_, to_TO the_DT great_JJ detriment_NN of_IN patients_NNS
        [_NN 7_CD –_NN 9_CD ]_NN ._.
        The_DT risks_NNS to_TO a_DT journal_NN in_IN sponsoring_VBG such_JJ an_DT event_NN are_VBP ,_, of_IN course_NN ,_, much_RB smaller_JJR than_IN the_DT
        risks_NNS that_IN the_DT whistleblowers_NNS at_IN the_DT roundtable_JJ faced_VBN in_IN going_VBG public_NN with_IN their_PRP$ stories_NNS ._.
        Studies_NNS have_VBP shown_VBN that_IN whistleblowers_NNS in_IN both_DT public_JJ service_NN and_CC private_JJ industry_NN almost_RB
        always_RB experience_VB retaliation_NN from_IN their_PRP$ employers_NNS ,_, with_IN those_DT employed_VBN longer_RBR experiencing_VBG
        greater_JJR retaliation_NN [_NN 10_CD ,_, 11_CD ]_NN ._. They_PRP risk_VBP loss_NN of_IN earnings_NNS ,_, intimidation_NN ,_, harassment_NN ,_,
        victimization_NN ,_, and_CC personal_JJ abuse_NN ,_, and_CC they_PRP traditionally_RB receive_VBP little_JJ help_NN from_IN
        statutory_JJ authorities_NNS [_NN 12_CD ,_, 13_CD ]_NN ._.
        The_DT Washington_NNP whistleblowers_NNS '_POS stories_NNS illustrate_VBP these_DT issues_NNS ._. Psychiatrist_NNP Stefan_NNP
        Kruszewski_NNP described_VBD how_WRB he_PRP was_VBD fired_VBN from_IN his_PRP$ job_NN at_IN the_DT Pennsylvania_NNP Department_NNP of_IN Public_NNP
        Welfare_NNP (_( DPW_NNP )_) after_IN alerting_VBG his_PRP$ seniors_NNS to_TO prescribing_VBG practices_NNS across_IN the_DT state_NN that_IN he_PRP
        considered_VBD to_TO be_VB alarming_JJ and_CC dangerous_JJ [_NN 2_CD ]_NN ._. “ I_PRP was_VBD fired_VBN in_IN a_DT demeaning_JJ manner_NN ,_,” said_VBD
        Kruszewski_NNP ,_, who_WP has_VBZ sued_VBN DPW_NNP over_IN his_PRP$ firing_NN ._. “ My_PRP$ two_CD offices_NNS were_VBD emptied_VBN and_CC the_DT contents_NNS
        of_IN these_DT offices_NNS were_VBD put_VBN in_IN the_DT gutter_NN ._.” David_NNP Graham—who_NNP testified_VBD at_IN a_DT US_NNP Senate_NNP Finance_NNP
        Committee_NNP hearing_NN on_IN rofexocib_NN (_( Vioxx_NNP )_) ,_, the_DT FDA_NNP ,_, and_CC Merck_NNP [_NN 1_CD ]_NN —_NN said_VBD that_IN there_EX was_VBD a_DT
        conspiracy_NN by_IN senior_JJ management_NN at_IN the_DT FDA_NNP “ to_TO intimidate_VB me_PRP ahead_RB of_IN the_DT Senate_NNP
        testimony_NN ._.” Both_DT of_IN these_DT individuals_NNS contend_VBP that_IN pharmaceutical_JJ industry_NN influence_NN over_IN
        their_PRP$ employers_NNS (_( a_DT state_NN and_CC a_DT federal_JJ regulatory_JJ agency_NN ,_, respectively_RB )_) played_VBD a_DT part_NN in_IN
        the_DT difficulties_NNS these_DT individuals_NNS faced_VBN in_IN getting_VBG their_PRP$ concerns_NNS heard_VBD [_NN 1_CD ,_, 2_CD ]_NN ._.
        Lenzer_NNP 's_POS report_NN will_MD ,_, we_PRP hope_VB ,_, spark_VB discussion_NN and_CC debate_NN about_IN how_WRB American_JJ
        medicine—clinicians_NNS ,_, researchers_NNS ,_, regulatory_JJ agencies_NNS ,_, and_CC medical_JJ journals—can_NN disentangle_NN
        itself_PRP from_IN the_DT influence_NN of_IN the_DT pharmaceutical_JJ industry_NN ._. In_IN the_DT past_JJ ,_, medical_JJ journals_NNS and_CC
        their_PRP$ editors_NNS have_VBP played_VBN an_DT important_JJ part_NN in_IN exposing_VBG the_DT complex_JJ relationships_NNS between_IN
        the_DT pharmaceutical_JJ industry_NN and_CC medicine_NN [_NN 14_CD –_NN 16_CD ]_NN ,_, including_VBG between_IN industry_NN and_CC the_DT
        medical_JJ journals_NNS themselves_PRP [_NN 9_CD ]_NN ._. 
        PLoS_NNP Medicine_NNP will_MD continue_VB to_TO look_VB critically_RB at_IN these_DT relationships_NNS ._. A_DT
        common_JJ theme_NN at_IN the_DT roundtable_JJ was_VBD that_IN ,_, armed_VBN with_IN information_NN ,_, the_DT public_NN too_RB could_MD have_VB
        an_DT important_JJ role_NN in_IN unpicking_VBG these_DT ties_NNS ._. “ The_DT pharma–_NN FDA_NNP complex_NN has_VBZ to_TO be_VB dismantled_VBN ,_,”
        said_VBD Graham_NNP ,_, “ and_CC the_DT American_JJ people_NNS have_VBP to_TO insist_VB on_IN that_DT ,_, otherwise_RB we_PRP 're_VBP going_VBG to_TO have_VB
        disasters_NNS like_IN Vioxx_NNP that_WDT happen_VBP in_IN the_DT future_NN ._.” Patients_NNS ,_, health_NN professionals_NNS ,_, and_CC even_RB
        the_DT industry_NN itself_PRP all_DT surely_RB stand_NN to_TO gain_VB from_IN disentanglement_NN ._.
      
    
  
